Association Between Body Weight And Efficacy Outcomes During Trabectedin Therapy For Recurrent Advanced Soft Tissue Sarcoma (Sts)

10047 Background: Trabectedin is the first marine-derived antineoplastic drug approved in Europe for the treatment of patients with recurrent advanced STS. Different studies have implicated tumor-derived cytokines as mediators of cachexia in cancer patients. Preclinical studies have demonstrated that trabectedin acts on tumor microenvironment particularly reducing IL-6, which is involved in cancer-induced cachexia (Germano et al. 2011, Ligouri et al. 2011). Methods: This exploratory retrospective analysis evaluated the association between body weight increase during treatment with respect to baseline and efficacy outcomes in 319 adult patients with recurrent STS. Patients were treated in four phase II trials with trabectedin at the approved dose of 1.5 mg/m2, given as a 24-hour infusion every 3 weeks. An analysis of the concordance between weight increase and objective response (OR) rate, tumor control (TC) rate (OR+stable disease lasting ≥3 months), progression-free survival (PFS) and overall survival (O...